With continued progress on established platforms, new acquisitions and new products, Abbott (NYSE:ABT) has high expectations for its Diabetes business. Speaking at the J.P. Morgan Healthcare Conference, CEO Robert Ford highlighted diabetes as a key area for near-term growth. Specifically, in the presentation transcribed by SeekingAlpha, Ford said he expects the FreeStyle Libre continuous glucose […]
Diabetes
How Dexcom designed a new ‘life-changing’ sensor for even more people with diabetes
Dexcom (Nasdaq:DXCM) Chair, President and CEO Kevin Sayer says that, in 2019, he gave a speech announcing the company’s first $1 billion year. This week, Sayer announced the continuous glucose monitor maker’s first $1 billion quarter. Plenty of innovation has bolstered that progress over the past few years. Nearly one year ago, Dexcom launched its […]
Dexcom submits new glucose sensor to FDA, expects launch this summer
Dexcom (Nasdaq:DXCM) announced that it submitted its new Stelo glucose sensor to the FDA for review at the end of last year. The continuous glucose monitor (CGM) maker designed Stelo specifically for people with type 2 diabetes who do not use insulin. San Diego-based Dexcom designed Stelo for a 15-day wear with a cash-pay option. […]
Embecta submits insulin patch pump for FDA clearance
Embecta (Nasdaq:EMBC) announced today that it submitted a 510(k) premarket filing to the FDA for its proprietary insulin patch pump. The Parsippany, New Jersey-based BD Diabetes spinoff developed a proprietary, disposable pump for people with type 2 diabetes. The company provided analysts with some details on the makeup of the open-loop system earlier this year. It […]
Insulet has a Class I recall for the Omnipod 5 Android App
The FDA labeled a recall of the Insulet (Nasdaq:PODD) Omnipod 5 App for Android smartphones as Class I, the most serious kind. Insulet’s recall — a correction, not a product removal — affects software versions 1.1-1.2.3 for the Omnipod 5 automated insulin delivery system. It distributed the software between April 20, 2023, and Dec. 20, […]
Medtronic wins CE mark for MiniMed 780G with Simplera Sync disposable, all-in-one CGM
Medtronic (NYSE:MDT) announced today that it received CE mark approval for its MiniMed 780G system with Simplera Sync. Simplera Sync, a disposable, all-in-one continuous glucose monitor (CGM), eliminates the need for fingersticks and overtape. It features an improved user experience at half the size of previous Medtronic sensors with a simple, two-step insertion process. MiniMed […]
Abbott integrates FreeStyle Libre 2 Plus into Tandem’s automated insulin pump
Abbott (NYSE:ABT) and Tandem Diabetes Care (Nasdaq:TNDM) today announced the integration of FreeStyle Libre 2 Plus CGM into the t:slim X2 insulin pump. This marks the first automated insulin delivery system to integrate the newly available Abbott FreeStyle Libre 2 Plus sensor. The FDA cleared the updated Abbott continuous glucose monitor (CGM) for use with […]
Better Therapeutics, Glooko partner on digital diabetes management
Better Therapeutics and Glooko today announced a partnership to integrate technologies and enhance diabetes management. The partnership aims to integrate Better Therapeutics’ ApsyreRx digital behavioral treatment into Glooko’s diabetes management platform. Better Therapeutics designed AspyreRx to treat type 2 diabetes. The FDA authorized AspyreRx as a prescription digital therapeutic for diabetes in July. Palo Alto, […]
UK receives funding for automated insulin pump rollout this year
Following new government guidance, the UK’s National Health Service (NHS) has plans to roll out automated insulin delivery systems. Last month, the National Institute for Health and Care Excellence (NICE) issued guidance supporting automated insulin delivery for type 1 diabetes. NICE published guidance recommending hybrid closed-loop systems for eligible people with type 1 diabetes in […]
Glucotrack has positive data for implantable continuous blood glucose monitor
Glucotrack (Nasdaq:GCK) announced today that it completed the first preclinical study of its implantable continuous blood glucose monitor (CBGM). Rutherford, New Jersey-based Glucotrack aimed to assess the implant technique and device safety in the study. Additionally, the study used a small sample size of sensors to determine device functionality. Despite no intent to conduct an […]